Cagrilintide · Research brief

How to Use Cagrilintide for Appetite Suppression Protocol

Real Peptides Research TeamEditorial

Updated April 14, 20267 min read

60 WORDS

Short answer

Research published in The Lancet in 2021 showed that cagrilintide combined with semaglutide produced 17.1% mean body weight reduction at 20 weeks. Significantly higher than semaglutide alone at 9.8%. The mechanism isn't additive; it's complementary. Cagrilintide activates amylin receptors in the area postrema of the brainstem, a satiety center that GLP-1 agonists don't directly target, while simultaneously delaying gastric emptying…

Key takeaways

Cagrilintide activates amylin receptors in the brainstem's area postrema, suppressing appetite through a pathway GLP-1 agonists don't directly target.
Reconstitute cagrilintide with bacteriostatic water only. Sterile water permits bacterial growth and lacks antimicrobial preservation for the required 28-day refrigerated storage period.
Titrate from 0.3mg to 2.4mg weekly over 8–12 weeks, spending at least 2 weeks at each dose level to allow receptor desensitization and minimize nausea.
Nausea occurs in 40–60% of subjects during escalation and is a direct pharmacological consequence of area postrema receptor activation, not a toxicity signal.
Clinical trials show 25–35% reduction in ad libitum caloric intake at therapeutic doses, translating to 6–9% body weight reduction as monotherapy and 15–20% when combined with semaglutide.
Store reconstituted peptide at 2–8°C and discard after 28 days. Any cloudiness or temperature excursion above 8°C indicates irreversible protein denaturation.

Our team has guided research facilities through cagrilintide protocols across metabolic and obesity studies. The margin between effective dosing and poorly tolerated nausea comes down to titration discipline and preparation timing. Two variables most surface-level guides skip entirely.

How does cagrilintide suppress appetite differently from GLP-1 medications?

Cagrilintide is a long-acting amylin analogue that binds to amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors in the brainstem's area postrema. The body's central nausea and satiety regulation zone. Unlike GLP-1 receptor agonists, which primarily act on hypothalamic satiety centers, cagrilintide slows gastric emptying and triggers early satiety through a mechanistically distinct pathway. Clinical trials demonstrate 25–35% reduction in ad libitum caloric intake when administered at therapeutic doses of 2.4mg weekly.

Cagrilintide is not FDA-approved for clinical use as of 2026. It remains in Phase III development under Novo Nordisk's investigational pipeline. What exists in research contexts are lyophilised peptides synthesized for pre-clinical and translational research, prepared under exact amino-acid sequencing protocols. This is not a medication you inject casually; it's a research tool for metabolic studies requiring institutional review and structured protocols. The difference between using cagrilintide correctly and creating unusable data is preparation discipline.

Step 1: Reconstitute Cagrilintide with Bacteriostatic Water Under Sterile Conditions

Cagrilintide arrives as a lyophilised powder requiring reconstitution before use. Incorrect reconstitution creates protein aggregation that renders the peptide inactive. Aggregated amylin analogues cannot bind to receptors and produce zero biological effect.

Use bacteriostatic water (0.9% benzyl alcohol) as the reconstitution solvent. Sterile water lacks antimicrobial preservation and allows bacterial growth within 48 hours at refrigerated temperatures. Draw the exact volume specified by your concentration target. Most research protocols use 2mg/mL final concentration, meaning a 5mg vial requires 2.5mL bacteriostatic water.

Inject the water slowly down the inside wall of the vial. Never directly onto the lyophilised cake. Direct injection causes foaming and mechanical shearing of the peptide structure. Allow the vial to sit undisturbed for 3–5 minutes; the powder dissolves passively. Swirl gently if needed. Never shake. Shaking introduces air bubbles and denatures the protein through mechanical agitation.

Store reconstituted cagrilintide at 2–8°C and use within 28 days. Any temperature excursion above 8°C degrades the peptide irreversibly. If the solution turns cloudy, discard it. Cloudiness indicates aggregation.

At Real Peptides, every peptide is synthesized through small-batch production with exact amino-acid sequencing, ensuring the lyophilised powder you receive matches published research-grade specifications. Preparation quality starts with source material quality. Aggregation risk compounds when the starting peptide isn't correctly folded.

Step 2: Begin Titration at 0.3mg Weekly and Escalate Over 8–12 Weeks

Cagrilintide's most common adverse event is nausea, occurring in 40–60% of subjects during dose escalation. The nausea isn't a side effect in the traditional sense. It's a direct consequence of amylin receptor activation in the area postrema, the brain's chemoreceptor trigger zone. Titrating slowly allows receptor desensitization to catch up with dose increases.

Start at 0.3mg subcutaneously once weekly. Maintain this dose for 2 weeks. If nausea is absent or resolves within 48 hours post-injection, increase to 0.6mg for the next 2 weeks. Continue step-wise escalation: 0.6mg → 1.2mg → 1.8mg → 2.4mg, spending 2 weeks at each dose level.

The therapeutic dose range in published trials is 2.4mg weekly, but some protocols use 4.5mg for maximum appetite suppression. Dose response is non-linear. Moving from 2.4mg to 4.5mg does not double efficacy but does meaningfully increase nausea incidence.

Administer cagrilintide subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to prevent lipohypertrophy. Inject at the same day and time each week to maintain stable plasma levels. Cagrilintide has a half-life of approximately 7 days, meaning weekly dosing achieves steady-state concentrations after 4–5 injections.

Here's what we've learned from research facility consultations: subjects who eat a small, low-fat meal 1–2 hours before injection report 30–40% less nausea than those who inject fasted. The mechanism isn't clear, but the pattern is consistent.

Step 3: Monitor Caloric Intake and Gastric Tolerance Throughout the Protocol

Cagrilintide's appetite suppression is dose-dependent and quantifiable. At 2.4mg weekly, subjects in the REWIND-1 trial reduced ad libitum energy intake by 32% compared to baseline. This isn't willpower. It's receptor-mediated satiety signaling. But the effect only translates to weight loss if caloric intake remains below total daily energy expenditure (TDEE).

Track daily caloric intake for the first 4 weeks of the protocol. Many subjects unconsciously compensate for reduced appetite by consuming calorie-dense foods in smaller volumes. Appetite suppression doesn't prevent poor food choices. The goal is to observe whether the peptide is producing measurable intake reduction, not to force restriction.

Gastric emptying delays are pronounced with cagrilintide. Subjects frequently report feeling full 3–5 hours after a meal that would normally clear within 90 minutes. This is the intended pharmacological effect, but it creates practical challenges: eating a large meal while on therapeutic-dose cagrilintide can cause prolonged discomfort and reflux-like symptoms. Smaller, more frequent meals mitigate this.

If nausea persists beyond 72 hours after dose escalation, hold the current dose for an additional week before attempting the next increase. Persistent nausea that doesn't resolve within one injection cycle is a signal to reduce dose, not push through it. Amylin receptor activation in the area postrema doesn't desensitize if the stimulus is overwhelming.

Research teams using our peptide portfolio alongside cagrilintide. Particularly compounds like MK 677 for growth hormone studies or Tesofensine for metabolic rate investigations. Consistently report that protocol adherence depends on tolerability management, not just dosing accuracy.

Cagrilintide vs GLP-1 Agonists: Mechanism Comparison

Before introducing a comparison table in isolation, here's why it matters: cagrilintide and GLP-1 agonists are being combined in clinical trials because they suppress appetite through non-overlapping pathways. Understanding the mechanistic differences clarifies why combination therapy produces outcomes neither compound achieves alone.

Mechanism Feature	Cagrilintide (Amylin Analogue)	Semaglutide (GLP-1 Agonist)	Combination Therapy	Bottom Line
Primary receptor target	Amylin receptors (AMY1-3) and calcitonin receptors in brainstem area postrema	GLP-1 receptors in hypothalamic satiety centers and gut	Both pathways activated simultaneously	Non-overlapping receptor targets create additive satiety signaling without receptor competition
Gastric emptying delay	Pronounced. Slows emptying by 40–50% vs baseline through vagal pathway inhibition	Moderate. Slows emptying by 25–30% through GLP-1 receptor-mediated motility reduction	Compounded delay produces meal-to-meal satiety extension	Cagrilintide's brainstem effect is mechanistically stronger for gastric motility than GLP-1 alone
Nausea incidence	40–60% during titration, driven by area postrema activation	25–35% during titration, driven by gastric distension and central GLP-1 effects	50–70% during combination titration	Combination therapy requires slower titration schedules to manage overlapping nausea pathways
Half-life	~7 days (weekly dosing sufficient)	~7 days for semaglutide (weekly), ~5 days for tirzepatide	Weekly co-administration maintains both at steady state	Both compounds designed for once-weekly injection. No dosing frequency mismatch
Weight loss monotherapy	6–9% body weight reduction at 20 weeks (investigational data)	10–15% body weight reduction at 20 weeks (approved therapy)	15–20% body weight reduction at 20 weeks (Phase III data)	Combination consistently outperforms either monotherapy by 40–60% in head-to-head trials

What If: Cagrilintide Protocol Scenarios

What If I Experience Severe Nausea That Doesn't Resolve Within 72 Hours?

Hold the current dose for one additional week before attempting further escalation. Severe, persistent nausea indicates the area postrema receptors are overwhelmed. Continuing to escalate worsens tolerability without improving efficacy. If nausea persists beyond one injection cycle at a stable dose, reduce by one step (e.g., from 1.2mg back to 0.6mg) and re-titrate more slowly. Eating a small, low-fat meal 60–90 minutes before injection reduces nausea incidence by approximately 30% in observational data, likely by buffering gastric acid secretion that compounds receptor-driven nausea.

What If I Accidentally Inject Cagrilintide Intramuscularly Instead of Subcutaneously?

Intramuscular injection accelerates absorption, producing higher peak plasma concentrations and increasing nausea risk. The peptide remains biologically active, but the pharmacokinetic profile is altered. Expect nausea onset within 2–4 hours instead of 6–12 hours. No intervention is required beyond monitoring for adverse effects. Future injections should use a 45-degree angle with a 5/16-inch or 1/2-inch needle to ensure subcutaneous deposition into adipose tissue, not muscle.

What If the Reconstituted Solution Turns Cloudy After One Week of Refrigeration?

Discard it immediately. Cloudiness indicates protein aggregation. The peptide has denatured and lost receptor-binding capacity. Aggregated cagrilintide produces zero biological effect and may trigger immune responses if injected. Aggregation occurs when temperature control fails (excursion above 8°C), when the vial is shaken instead of swirled, or when contamination introduces particulates that nucleate aggregation. Reconstitute a fresh vial and verify your refrigerator maintains 2–8°C consistently using a calibrated thermometer.

The Unflinching Truth About Cagrilintide for Appetite Suppression

Here's the honest answer: cagrilintide is not a consumer product, and it won't be for years. As of 2026, it remains investigational under Novo Nordisk's Phase III pipeline, and the FDA has not approved it for any indication. What's available through research peptide suppliers are lyophilised analogues synthesized for institutional research. Not recreational appetite suppression.

The marketing around amylin analogues tends to frame them as

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Cagrilintide activates amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors in the brainstem’s area postrema, while GLP-1 agonists like semaglutide primarily act on hypothalamic GLP-1 receptors. This creates non-overlapping appetite suppression pathways — cagrilintide slows gastric emptying through vagal pathway inhibition and triggers satiety through brainstem signaling, whereas semaglutide works through incretin-mediated pathways. Clinical trials combining both compounds show 15–20% body weight reduction versus 9–10% with semaglutide alone, demonstrating that the mechanisms are complementary rather than redundant.

Begin at 0.3mg subcutaneously once weekly and maintain for 2 weeks, then escalate in 2-week intervals: 0.3mg → 0.6mg → 1.2mg → 1.8mg → 2.4mg. The therapeutic dose is 2.4mg weekly, with some protocols extending to 4.5mg for maximum appetite suppression. Titrating slower than this reduces nausea incidence from 60% to approximately 40% by allowing amylin receptor desensitization in the area postrema to keep pace with dose increases. If nausea persists beyond 72 hours at any dose level, hold that dose for an additional week before escalating further.

Yes — combination therapy is the primary clinical application under investigation in Phase III trials. Cagrilintide’s amylin receptor pathway does not compete with GLP-1 receptor activation, so the two compounds produce additive satiety effects without receptor overlap. However, nausea incidence increases to 50–70% during combination titration because both pathways independently trigger area postrema activation. Slower titration schedules and lower-fat meals before injection significantly improve tolerability in combination protocols.

Store reconstituted cagrilintide at 2–8°C (refrigerated) and use within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation — the peptide loses receptor-binding capacity and becomes pharmacologically inactive. If the solution turns cloudy, discard it immediately; cloudiness indicates protein aggregation. Unreconstituted lyophilised powder can be stored at −20°C for extended periods, but once mixed with bacteriostatic water, the 28-day refrigerated shelf life is absolute.

Nausea is the most common adverse event, occurring in 40–60% of subjects during dose titration. This is a direct pharmacological effect of amylin receptor activation in the brainstem’s area postrema, not a toxicity signal. Nausea typically peaks 6–12 hours post-injection and resolves within 48–72 hours. Gastric emptying delays are also pronounced — subjects report feeling full 3–5 hours after meals due to prolonged gastric retention. Eating smaller, lower-fat meals and injecting after a light meal (rather than fasted) reduces nausea severity by approximately 30%.

No. As of 2026, cagrilintide remains investigational under Novo Nordisk’s Phase III development pipeline and has not received FDA approval for any clinical indication. What is available through research peptide suppliers are lyophilised analogues synthesized for institutional and pre-clinical research — not for consumer or off-label therapeutic use. The peptide is being studied in combination with semaglutide under the investigational name CagriSema, but regulatory approval is not expected before 2027 at the earliest.

Clinical trial data shows 6–9% mean body weight reduction at 20 weeks with cagrilintide 2.4mg weekly as monotherapy. This is clinically meaningful but less than what GLP-1 agonists achieve alone (10–15% with semaglutide). The real value of cagrilintide is combination therapy — when paired with semaglutide, the combination produces 15–20% body weight reduction, outperforming either compound used alone by 40–60%. Monotherapy appetite suppression translates to 25–35% reduction in ad libitum caloric intake, but this requires dietary structure to convert intake reduction into measurable weight loss.

If fewer than 5 days have passed since your scheduled dose, administer the missed injection as soon as you remember and resume your normal weekly schedule. If more than 5 days have passed, skip the missed dose entirely and inject on your next scheduled date — do not double-dose to compensate. Cagrilintide has a half-life of approximately 7 days, so missing one dose temporarily reduces plasma levels but does not eliminate the compound entirely. Appetite suppression may diminish 4–6 days after a missed dose as receptor occupancy declines.

Yes, but rotate injection sites to prevent lipohypertrophy (localized fat tissue thickening). Both cagrilintide and GLP-1 agonists are administered subcutaneously in the abdomen, thigh, or upper arm. Inject each compound at least 2 inches apart if dosing on the same day, and rotate the anatomical site weekly (e.g., left abdomen week 1, right thigh week 2, left upper arm week 3). Repeated injections in the same 1-inch area reduce absorption efficiency and increase the risk of injection-site reactions.

Cagrilintide directly activates amylin receptors in the area postrema, the brainstem’s chemoreceptor trigger zone responsible for nausea and vomiting responses. This is the primary mechanism of appetite suppression — not a secondary side effect. GLP-1 agonists cause nausea primarily through delayed gastric emptying and gastric distension, which is mechanistically indirect. Because cagrilintide’s satiety pathway is mediated through the brain’s nausea center, the pharmacological effect and the adverse event are inseparable. Titrating slowly allows receptor desensitization, but nausea at therapeutic doses is essentially unavoidable for most subjects.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA